Neovaskularisationsglaukome sind eine große Herausforderung. Sie treten meist im Spätstadium einer Vielzahl von Gefäßerkrankungen der Netzhaut auf, die als gemeinsame Endstrecke eine ischämisch-proliferative Retinopathie entwickelt haben. Ihre Prognose ist ernst, immerhin erfolgen 12–15 Prozent aller Enukleationen wegen eines neovaskulären Glaukoms [4].
Entsprechend vielfältig sind die Anforderungen an eine effektive Behandlung, die ein optimiertes Patientenmanagement an der Schnittstelle zwischen Glaukomatologie und Retinologie erfordert:
Wie können derartige Verläufe frühzeitig erkannt und ihre Komplikationen vermieden werden?
Welche drucksenkenden Konzepte (medikamentöse Glaukomtherapie, zyklodestruktive Glaukomchirurgie, filtrierende Glaukomchirurgie, Drainage-Implantate) sind bei diesen speziellen Patienten anwendbar?
Welche retinologischen Behandlungskonzepte (panretinale Laserkoagulation, intravitreale oder intrakamerale Injektionen, Pars-plana-Vitrektomie) müssen primär durchgeführt oder parallel eingeleitet werden?
Literatur
1
The Diabetic Retinopathy Study Research Group .
Indications for photocoagulation treatment of diabetic retinopathy.
Int Ophthalmol Clin.
1987;
27
239-253
2
The Central Vein Occlusion Study Group .
Natural history and clinical management of central retinal vein occlusion.
Arch Ophthalmol.
1997;
115
486-491
3
Macugen Retinopathy Diabetic Study Group .
Changes in retinal neovascularisation after pegaptanib (macugen) therapy in diabetic individuals.
Ophthalmology.
2006;
113
23-28
5
Aiello L P, Avery R L, Arrigg P G et al.
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.
N Engl J Med.
1994;
331
1480-1487
9 Brown G C, Brown M M. The ocular ischemic syndrome. Joussen AM, Gardner T, Kirchhof B, Ryan SJ Retinal vascular disease. Heidelberg; Springer 2007: 519-527
10
Browning D J, Scott A Q, Peterson C B et al.
The risk of missing angle neovascularization by omitting screening gonioscopy in acute central retinal vein occlusion.
Ophthalmology.
1998;
105
776-784
14
Eid T E, Katz L J, Spaeth G L et al.
Tube-shunt surgery versus neodymium:YAG cyclophotocoagulation in the management of neovascular glaucoma.
Ophthalmology.
1997;
104
1692-1700
15
Eid T M, Radwan A, el-Manawy W et al.
Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy.
Can J Ophthalmol.
2009;
44
451-456
16
Fakhraie G, Katz L, Prasad A et al.
Surgical outcomes of intravitreal bevacizumab and guarded filtration surgery in neovascular glaucoma.
Journal of Glaucoma.
2009;
, Epub ahead of print
17
Falavarjani K, Modarres M, Nazari H.
Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy.
Eye.
2009;
, Epub ahead of print
20
Iliev M E, Domig D, Wolf-Schnurrbursch U et al.
Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.
Am J Ophthalmol.
2006;
142
1054-1056
21 Joussen A M, Adamis A P. Inflammation as a stimulus for vascular leakage and proliferation. Joussen AM, Gardner T, Kirchhof B, Ryan SJ Retinal vascular disease. Heidelberg; Springer 2007: 97-107
22
Katz G J, Higginbotham E J, Lichter P R et al.
Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up.
Ophthalmology.
1995;
102
1263-1269
24
Lim T H, Bae S H, Cho Y J et al.
Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma.
Korean J Ophthalmol.
2009;
23
188-192
28
Matsuyama K, Ogata N, Jo N et al.
Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab.
Jpn J Ophthalmol.
2009;
53
243-248
29
Mermoud A, Salmon J F, Alexander P et al.
Molteno tube implantation for neovascular glaucoma. Long-term results and factors influencing the outcome.
Ophthalmology.
1993;
100
897-902
34
Oshima Y, Sakaguchi H, Gomi F et al.
Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy.
Am J Ophthalmol.
2006;
142
155-158
36
Saito Y, Higashide T, Takeda H et al.
Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma.
Acta Ophthalmol.
2009;
, Epub ahead of print
38
Scott I U, Alexandrakis G, Flynn H W et al.
Combined pars plana vitrectomy and glaucoma drainage implant placement for refractory glaucoma.
Am J Ophthalmol.
2000;
129
334-341
39
Shields M B, Shields S E.
Noncontact transscleral Nd:YAG cyclophotocoagulation: a long-term follow-up of 500 patients.
Trans Am Ophthalmol Soc.
1994;
92
271-287
40
Shin J P, Lee J W, Sohn B J, Kim H K et al.
In vivo corneal endothelial safety of intracameral bevacizumab and effect in neovascular glaucoma combined with ahmed valve implantation.
J Glaucoma.
2009;
18
589-594
41
Sidoti P A, Dunphy T R, Baerveldt G et al.
Experience with the Baerveldt glaucoma implant in treating neovascular glaucoma.
Ophthalmology.
1995;
102
1107-1118
42
Sivak-Callcott J A, O'Day D M, Gass J D et al.
Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma.
Ophthalmology.
2001;
108
1767-1776
quiz 1777
1800
43
Takihara Y, Inatani M, Fukushima M et al.
Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure.
Am J Ophthalmol.
2009;
147
912-918
44
Tsai J C, Feuer W J, Parrish R K et al.
5-Fluorouracil filtering surgery and neovascular glaucoma. Long-term follow-up of the original pilot study.
Ophthalmology.
1995;
102
887-893
48
Wakabayashi T, Oshima Y, Sakaguchi H et al.
Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Ophthalmologie.
2008;
115
1571-1580
50
Yildirim N, Yalvac I S, Sahin A et al.
A comparative study between diode laser cyclophotocoagulation and the Ahmed glaucoma valve implant in neovascular glaucoma: a long-term follow-up.
J Glaucoma.
2009;
18
192-196
